适配体BT200阻断VWF-A1结构域K1405-K1408与巨噬细胞LRP1的相互作用
本研究探讨BT200(现称Rondaptivon pegol)减少VWF清除的机制。体外实验显示BT200浓度依赖性抑制VWF-A1A2A3及全长VWF与巨噬细胞和LRP1的结合,且作用于K1405-K1408簇附近。该簇丙氨酸突变显著减弱VWF与LRP1簇II和IV结合及体内清除,BT200对突变体结合无显著抑制。
要点
- BT200浓度依赖性抑制VWF与巨噬细胞及LRP1的结合。
- K1405-K1408簇突变显著减弱VWF与LRP1簇II和IV结合及体内清除(P<.001)。
- BT200抑制VWF与巨噬细胞半乳糖凝集素和SR-AI清道夫受体结合。
核心结论
- BT200通过与VWF-A1结构域中K1405-K1408附近区域相互作用,减弱巨噬细胞介导的VWF清除,从而延长VWF半衰期。
研究设计与样本
- 体外结合实验及体内清除实验研究,使用全长VWF、VWF-A1A2A3片段、VWF-4A突变体及HEK293T(HEK-LRP1)细胞。
主要发现
- BT200浓度依赖性抑制全长VWF及VWF-A1A2A3与巨噬细胞的结合,也抑制VWF-A1结构域与LRP1簇II和簇IV的结合。
- BT200也抑制全长VWF与表达于HEK293T细胞(HEK-LRP1)的LRP1结合。
- K1405-K1408簇丙氨酸突变(VWF-4A)显著减弱VWF与LRP1簇II和簇IV的结合(P<.001)。
- VWF-4A的体内清除较野生型VWF显著减少(P<.001)。
- BT200对VWF-4A与LRP1簇IV或HEK-LRP1细胞的结合无显著抑制。
临床怎么用
- 作者认为靶向抑制VWF清除通路可能为血管性血友病和A型血友病提供新的治疗思路。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rondaptivon pegol (previously BT200) is a pegylated RNA aptamer that binds to the A1 domain of von Willebrand factor (VWF). Recent clinical trials demonstrated that BT200 significantly increased plasma VWF-factor VIII levels by attenuating VWF clearance. The biological mechanism(s) through which BT200 attenuates in vivo clearance of VWF has not been defined. We hypothesized that BT200 interaction with the VWF-A1 domain may increase plasma VWF levels by attenuating macrophage-mediated clearance. We observed that full-length and VWF-A1A2A3 binding to macrophages and VWF-A1 domain binding to lipoprotein receptor-related protein 1 (LRP1) cluster II and cluster IV were concentration-dependently inhibited by BT200. Additionally, full-length VWF binding to LRP1 expressed on HEK293T (HEK-LRP1) cells was also inhibited by BT200. Importantly, BT200 interacts with the VWF-A1 domain in proximity to a conserved cluster of 4 lysine residues (K1405, K1406, K1407, and K1408). Alanine mutagenesis of this K1405-K1408 cluster (VWF-4A) significantly (P < .001) attenuated binding of VWF to both LRP1 clusters II and IV. Furthermore, in vivo clearance of VWF-4A was significantly (P < .001) reduced than that of wild-type VWF. BT200 did not significantly inhibit binding of VWF-4A to LRP1 cluster IV or HEK-LRP1 cells. Finally, BT200 interaction with the VWF-A1 domain also inhibited binding to macrophage galactose lectin and the SR-AI scavenger receptor. Collectively, our findings demonstrate that BT200 prolongs VWF half-life by attenuating macrophage-mediated clearance and specifically the interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1. These data support the concept that targeted inhibition of VWF clearance pathways represents a novel therapeutic approach for von Willebrand disease and hemophilia A.
引用
- Chion A, Byrne C, Atiq F, et al. The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1. Blood. 2024. PMID: 38996211. doi:10.1182/blood.2024024055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。